Early Biochemical, Oxidative-Stress, Inflammatory, and Clinical Features of Anthracycline-Associated Cardiac Injury and Dysfunction in Patients with Breast Cancer: A Prospective Clinical Toxicology Study

• Aeshah Muhana Mohammed

  Department of Chemistry, College of Education for Pure Science Ibn Al-Haitham, University of Baghdad, Baghdad, Iraq

Background: Anthracycline-associated cardiac injury remains an important limitation of breast-cancer chemotherapy. This study characterized early cardiac, oxidative-stress, antioxidant, inflammatory, and clinical findings observed during the same post-cycle-two assessment window.

Methods: This prospective clinical toxicology study included 150 women with breast cancer receiving anthracycline-containing chemotherapy. Measurements were obtained at baseline and after the second cycle. A composite early cardiac injury/cancer therapy-related cardiac dysfunction (CTRCD) classification comprised biomarker-defined myocardial injury without clinical dysfunction (n=10) and clinical CTRCD (n=32). Because post-cycle-two biomarkers and cardiac status were assessed concurrently, these biomarkers were analyzed descriptively and were not modeled as temporal predictors or evaluated by receiver operating characteristic analysis. Univariable logistic regression was restricted to baseline clinical factors.

Results: Forty-two participants met the composite classification and 108 did not. Baseline left ventricular ejection fraction (LVEF) and most baseline biomarkers were comparable, although baseline C-reactive protein (CRP) was higher in the composite group (8.56±5.92 vs 5.94±3.93 mg/L; P=0.010). After cycle two, the composite group had larger increases in troponin, N-terminal pro-B-type natriuretic peptide (NT-proBNP), creatine kinase-MB, lactate dehydrogenase, malondialdehyde, CRP, interleukin-6, and tumor necrosis factor-α, together with greater declines in LVEF, superoxide dismutase, glutathione peroxidase, catalase, and reduced glutathione (all change-score comparisons P<0.001). Hypertension (OR 2.87, 95% CI 1.36–6.06) and baseline LVEF <60% (OR 2.53, 95% CI 1.17–5.50) were associated with the composite classification in univariable analyses.

Conclusions: Early anthracycline-associated cardiac injury and dysfunction were accompanied by a concurrent multi-pathway profile of myocardial injury, wall stress, oxidative imbalance, antioxidant depletion, and inflammation. These findings support hypothesis-generating, multimodal surveillance research, but they do not establish temporal prediction or independent diagnostic performance for biomarkers measured during the same assessment window.

[1] Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024; 74(3): 229-263.

https://doi.org/10.3322/caac.21834

[2] Dauccia C, Agostinetto E, Arecco L, LoboMartins S, Gitto M, Lyon AR, et al. Cardiovascular toxicity of breast cancer treatments: from understanding to enhancing survivorship care. ESMO Open 2025; 10(6): 105128.

https://doi.org/10.1016/j.esmoop.2025.105128

[3] Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003; 97(11): 2869-2879.

https://doi.org/10.1002/cncr.11407

[4] Lyon AR, LópezFernández T, Couch LS, Asteggiano R, Aznar MC, BerglerKlein J, et al 2022 ESC Guidelines on cardiooncology developed in collaboration with the European Hematology Association, the European Society for Therapeutic Radiology and Oncology and the International CardioOncology Society. Eur Heart J 2022; 43(41): 4229-4361.

https://doi.org/10.1093/eurheartj/ehac244

[5] Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G, et al. Anthracyclineinduced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 2010; 55(3): 213-220.

https://doi.org/10.1016/j.jacc.2009.03.095

[6] Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, ScherrerCrosbie M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2014; 27(9): 911-939.

https://doi.org/10.1016/j.echo.2014.07.012

[7] Armenian SH, Lacchetti C, Barac A, Carver J, Constine LS, Denduluri N, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2017; 35(8): 893-911.

https://doi.org/10.1200/JCO.2016.70.5400

[8] Cardinale D, Sandri MT, Martinoni A, Tricca A, Civelli M, Lamantia G, et al. Left ventricular dysfunction predicted by early troponin I release after highdose chemotherapy. J Am Coll Cardiol 2000; 36(2): 517-522.

https://doi.org/10.1016/S07351097(00)007488

[9] Cardinale D, Sandri MT, Colombo A, Colombo N, Boeri M, Lamantia G, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients receiving highdose chemotherapy. Circulation 2004; 109(22): 2749-2754.

https://doi.org/10.1161/01.CIR.0000130926.51766.CC

[10] Putt M, Hahn VS, Januzzi JL Jr, Sawaya H, Sebag IA, Plana JC, et al. Longitudinal changes in multiple biomarkers are associated with cardiotoxicity in breast cancer patients treated with doxorubicin, taxanes, and trastuzumab. Clin Chem 2015; 61(9): 1164-1172.

https://doi.org/10.1373/clinchem.2015.241232

[11] Michel L, Mincu RI, Mahabadi AA, Settelmeier S, AlRashid F, Rassaf T, et al. Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a metaanalysis. Eur J Heart Fail 2020; 22(2): 350-361.

https://doi.org/10.1002/ejhf.1631

[12] Feng W, Wang Q, Tan Y, Qiao J, Liu Q, Yang B, Yang S, Cui L. Early detection of anthracyclineinduced cardiotoxicity. Clin Chim Acta 2025; 565: 120000.

https://doi.org/10.1016/j.cca.2024.120000

[13] Octavia Y, Tocchetti CG, Gabrielson KL, Janssens S, Crijns HJGM, Moens AL. Doxorubicininduced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol 2012; 52(6): 1213-1225.

https://doi.org/10.1016/j.yjmcc.2012.03.006

[14] Wallace KB. Doxorubicininduced cardiac mitochon-drionopathy. Pharmacol Toxicol 2003; 93(3): 105-115.

https://doi.org/10.1034/j.16000773.2003.930301.x

[15] Sawyer DB, Peng X, Chen B, Pentassuglia L, Lim CC. Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection? Prog Cardiovasc Dis 2010; 53(2): 105-113.

https://doi.org/10.1016/j.pcad.2010.06.007

[16] Nagy A, Börzsei D, Hoffmann A, Török S, Veszelka M, Almási N, et al. A comprehensive overview on chemotherapyinduced cardiotoxicity: insights into the underlying inflammatory and oxidative mechanisms. Cardiovasc Drugs Ther 2025; 39(5): 1185-1199.

https://doi.org/10.1007/s10557024075740

[17] von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology Statement: guidelines for reporting observational studies. Ann Intern Med 2007; 147(8): 573-577.

https://doi.org/10.7326/00034819147820071016000010

[18] Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods 2009; 41(4): 1149-1160.

https://doi.org/10.3758/BRM.41.4.1149

[19] Herrmann J, Lenihan D, Armenian S, Barac A, Blaes A, Cardinale D, et al. Defining cardiovascular toxicities of cancer therapies: an International CardioOncology Society consensus statement. Eur Heart J 2022; 43(4): 280-299.

https://doi.org/10.1093/eurheartj/ehab674

[20] BC Cancer. Dose Conversion for Anthracycline Exposure. Provincial Pharmacy Drug Information; 2025. Available from: https://www.bccancer.bc.ca/drugdatabasesite/ Documents/ Dose%20Conversion%20for%20Anthracycline%20Exposure. pdf. Accessed July 31, 2026.

[21] Ky B, Putt M, Sawaya H, French B, Januzzi JL Jr, Sebag IA, et al. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol 2014; 63(8): 809-816.

https://doi.org/10.1016/j.jacc.2013.10.061

[22] Romano S, Fratini S, Ricevuto E, Procaccini V, Stifano G, Mancini M, et al. Serial measurements of NTproBNP are predictive of nothighdose anthracycline cardiotoxicity in breast cancer patients. Br J Cancer 2011; 105(11): 1663-1668.

https://doi.org/10.1038/bjc.2011.439

[23] Lu X, Zhao Y, Chen C, Han C, Xue L, Xing D, Huang O, Tao M. BNP as a marker for early prediction of anthracyclineinduced cardiotoxicity in patients with breast cancer. Oncol Lett 2019; 18(5): 4992-5001.

https://doi.org/10.3892/ol.2019.10827

[24] Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Tan TC, et al. Early detection and prediction of cardiotoxicity in chemotherapytreated patients. Am J Cardiol 2011; 107(9): 1375-1380.

https://doi.org/10.1016/j.amjcard.2011.01.006

[25] Zhang S, Liu X, BawaKhalfe T, Lu LS, Lyu YL, Liu LF, et al. Identification of the molecular basis of doxorubicininduced cardiotoxicity. Nat Med 2012; 18(11): 1639-1642.

https://doi.org/10.1038/nm.2919

[26] Wallace KB, Sardão VA, Oliveira PJ. Mitochondrial determinants of doxorubicininduced cardiomyopathy. Circ Res 2020; 126(7): 926-941.

https://doi.org/10.1161/CIRCRESAHA.119.314681

[27] Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004; 56(2): 185-229.

https://doi.org/10.1124/pr.56.2.6

[28] Tocchetti CG, Cadeddu C, Di Lisi D, Femminò S, Madonna R, Mele D, et al. From molecular mechanisms to clinical management of antineoplastic druginduced cardiovascular toxicity: a translational overview. Antioxid Redox Signal 2019; 30(18): 2110-2153.

https://doi.org/10.1089/ars.2016.6930

[29] Koleini N, Nickel BE, Wang J, Roveimiab Z, Fandrich RR, Kirshenbaum LA, et al. Fibroblast growth factor2mediated protection of cardiomyocytes from the toxic effects of doxorubicin requires the mTOR/Nrf2/ HO1 pathway. Oncotarget 2017; 8(50): 87415-87430.

https://doi.org/10.18632/oncotarget.20558

[30] Lyon AR, Dent S, Stanway S, Earl H, BrezdenMasley C, CohenSolal A, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the CardioOncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International CardioOncology Society. Eur J Heart Fail 2020; 22(11): 1945-1960.

https://doi.org/10.1002/ejhf.1920

[31] Pudil R, Mueller C, Čelutkienė J, Henriksen PA, Lenihan D, Dent S, et al. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the CardioOncology Study Group of the Heart Failure Association and the CardioOncology Council of the European Society of Cardiology. Eur J Heart Fail 2020; 22(11): 1966-1983.

https://doi.org/10.1002/ejhf.2017

[32] Camilli M, Cipolla CM, Dent S, Minotti G, Cardinale DM. Anthracycline cardiotoxicity in adult cancer patients: JACC: CardioOncology stateoftheart review. JACC CardioOncol 2024; 6(5): 655-677.

https://doi.org/10.1016/j.jaccao.2024.07.016

• PDF
• SUPPL

• Original Research Articles

Copyright (c) 2028 Aeshah Muhana Mohammed

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.